<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Palisade Bio, Inc. — News on 6ix</title>
<link>https://6ix.com/company/palisade-bio-inc</link>
<description>Latest news and press releases for Palisade Bio, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/palisade-bio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a87e78dffbe2df10c623.webp</url>
<title>Palisade Bio, Inc.</title>
<link>https://6ix.com/company/palisade-bio-inc</link>
</image>
<item>
<title>Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-abstract-selected-for-poster-presentation-at-digestive-disease-week-ddw-2026</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-abstract-selected-for-poster-presentation-at-digestive-disease-week-ddw-2026</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDT Denver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI)</description>
</item>
<item>
<title>Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-to-present-at-the-needham-and-co-25th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-to-present-at-the-needham-and-co-25th-annual-healthcare-conference</guid>
<pubDate>Wed, 08 Apr 2026 13:00:00 GMT</pubDate>
<description>Virtual presentation scheduled for Thursday, April 16th at 2:15 PM ET Access the webcast here Denver, CO, April 08, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President & Chief Medical Officer, wi</description>
</item>
<item>
<title>Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-reports-positive-topline-data-from-phase-1b-clinical-study-of-pali-2108-in-fibrostenotic-crohns-disease</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-reports-positive-topline-data-from-phase-1b-clinical-study-of-pali-2108-in-fibrostenotic-crohns-disease</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase</description>
</item>
<item>
<title>Palisade Bio Announces Participation in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-participation-in-two-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-participation-in-two-upcoming-investor-conferences</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Carlsbad, CA, March 02, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company</description>
</item>
<item>
<title>Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-reports-rapid-clinical-histologic-and-new-mechanistic-colon-tissue-rna-sequencing-data-supporting-targeted-activity-of-pali-2108-at-ecco-2026</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-reports-rapid-clinical-histologic-and-new-mechanistic-colon-tissue-rna-sequencing-data-supporting-targeted-activity-of-pali-2108-at-ecco-2026</guid>
<pubDate>Mon, 23 Feb 2026 13:40:00 GMT</pubDate>
<description>Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulation Data presented at the 21st Congress of the European Crohn’</description>
</item>
<item>
<title>Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-appoints-global-ibd-precision-medicine-leader-bram-verstockt-md-phd-to-clinical-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-appoints-global-ibd-precision-medicine-leader-bram-verstockt-md-phd-to-clinical-advisory-board</guid>
<pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
<description>Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND</description>
</item>
<item>
<title>Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-participate-piper-sandler-140000088</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-participate-piper-sandler-140000088</guid>
<pubDate>Mon, 09 Feb 2026 14:00:00 GMT</pubDate>
<description>Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and</description>
</item>
<item>
<title>Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-present-oppenheimer-36th-134500343</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-present-oppenheimer-36th-134500343</guid>
<pubDate>Thu, 05 Feb 2026 13:45:00 GMT</pubDate>
<description>Virtual presentation scheduled for Thursday, February 26th at 12:40 PM ET Access the webcast here Carlsbad, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, President and Chief Medical Offi</description>
</item>
<item>
<title>Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-appoints-leading-global-134500300</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-appoints-leading-global-134500300</guid>
<pubDate>Thu, 29 Jan 2026 13:45:00 GMT</pubDate>
<description>Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s disease, and late-stage clinical trial design Appointments strengthen Palisade Bio’s clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn’s disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the</description>
</item>
<item>
<title>Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-two-abstracts-133000944</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-two-abstracts-133000944</guid>
<pubDate>Fri, 16 Jan 2026 13:30:00 GMT</pubDate>
<description>PALI-2108 Abstracts Highlight Gut-Targeted PDE4B Inhibition and Translational Phase 1a Findings in Ulcerative Colitis Carlsbad, CA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today announced that two abstracts highlighting its lead program, PALI-2108, have been select</description>
</item>
<item>
<title>Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-strategic-equity-131500054</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-strategic-equity-131500054</guid>
<pubDate>Wed, 07 Jan 2026 13:15:00 GMT</pubDate>
<description>PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) Carlsbad, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal</description>
</item>
<item>
<title>Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-granting-japanese-133500590</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-granting-japanese-133500590</guid>
<pubDate>Tue, 30 Dec 2025 13:35:00 GMT</pubDate>
<description>PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address significant unmet medical needs Ongoing development of PALI-2108 across FSCD and UC, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-ge</description>
</item>
<item>
<title>Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-strengthens-clinical-leadership-134500234</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-strengthens-clinical-leadership-134500234</guid>
<pubDate>Tue, 02 Dec 2025 13:45:00 GMT</pubDate>
<description>Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, M</description>
</item>
<item>
<title>Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-present-piper-sandler-134500226</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-present-piper-sandler-134500226</guid>
<pubDate>Tue, 25 Nov 2025 13:45:00 GMT</pubDate>
<description>Live webcast fireside chat on Thursday, December 4th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced JD Finley, Chief Executive Officer and Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, will participate in a fireside chat at t</description>
</item>
<item>
<title>Palisades Expands Nevada Gold Portfolio Through Acquisition of Undercover Gold by Made in America Gold Corp.</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisades-expands-nevada-gold-portfolio-through-acquisition-of-undercover-gold-by-made-in-america-gold-corp-3</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisades-expands-nevada-gold-portfolio-through-acquisition-of-undercover-gold-by-made-in-america-gold-corp-3</guid>
<pubDate>Mon, 17 Nov 2025 11:30:00 GMT</pubDate>
<description>Palisades Goldcorp Ltd. (TSXV: PALI) (the "Company" or "Palisades") is pleased to announce that its wholly owned subsidiary, Made in America Gold Corp. ("MIAG"), has entered into a non-binding Letter of Intent (the "LOI") to acquire, by way of a share purchase agreement, Undercover Gold Inc. ("Undercover"), which owns the South Cortez and South Tonkin mineral properties (together, the "Properties"). Undercover was founded by NewQuest Capital Inc. ("NewQuest") which is lead by an industry-recogni</description>
</item>
<item>
<title>PALISADES ANNOUNCES EXTENSION OF CONVERTIBLE NOTE</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisades-announces-extension-of-convertible-note-1</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisades-announces-extension-of-convertible-note-1</guid>
<pubDate>Tue, 11 Nov 2025 23:36:00 GMT</pubDate>
<description>Palisades Goldcorp Ltd. (TSXV: PALI) ("Palisades" or the "Company") announced today that further to its May 21, 2025 news release, the Company has agreed to extend the maturity date of its secured convertible note in the principal amount of C$4,161,600 (the "Note") from November 21, 2025 to May 21, 2026, subject to approval of the TSX Venture Exchange. As a result of its return of capital transaction completed on September 17, 2025, in accordance with the terms of the Note, the conversion price</description>
</item>
<item>
<title>Palisades Appoints Justin Daley as CEO of 100%-OwnedMade in America Gold</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisades-appoints-justin-daley-as-ceo-of-100percent-ownedmade-in-america-gold-3</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisades-appoints-justin-daley-as-ceo-of-100percent-ownedmade-in-america-gold-3</guid>
<pubDate>Mon, 03 Nov 2025 11:30:00 GMT</pubDate>
<description>Palisades Goldcorp Ltd. (TSXV: PALI) (the "Company" or "Palisades") is pleased to announce the appointment of Justin Daley, P.Geo., as Chief Executive Officer of Made in America Gold Corp. ("Made in America Gold"), a 100% owned subsidiary of Palisades. Mr. Daley will lead the exploration and strategic advancement of the Company's gold portfolio, covering over 700 km2 across the prolific Battle Mountain-Eureka Trend (Figure 1). Made in America Gold is the largest junior claim holder in the State</description>
</item>
<item>
<title>Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-appoints-sharon-skare-124500253</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-appoints-sharon-skare-124500253</guid>
<pubDate>Tue, 28 Oct 2025 12:45:00 GMT</pubDate>
<description>Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing precision</description>
</item>
<item>
<title>Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-first-patients-124500228</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-announces-first-patients-124500228</guid>
<pubDate>Mon, 20 Oct 2025 12:45:00 GMT</pubDate>
<description>First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing development of PALI-2108 across fibrostenotic Crohn’s disease and ulcerative colitis, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing</description>
</item>
<item>
<title>Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108</title>
<link>https://6ix.com/company/palisade-bio-inc/news/palisade-bio-granted-canadian-patent-124500073</link>
<guid isPermaLink="true">https://6ix.com/company/palisade-bio-inc/news/palisade-bio-granted-canadian-patent-124500073</guid>
<pubDate>Mon, 13 Oct 2025 12:45:00 GMT</pubDate>
<description>PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio,” or the “Company”), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intell</description>
</item>
</channel>
</rss>